WARS neutralizing antibodies and their uses
Antibodies specifically targeting WARS1 without cross-reactivity address the issue of ineffective treatment by suppressing WARS1 expression and associated cytokines, enhancing diagnostic and therapeutic efficacy for infectious diseases.
Patent Information
- Application Number
- JP2023527238
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-10-14
- Filing Date
- 2021-10-15
- Publication Date
- 2024-11-27
- Estimated Expiration
- 2041-10-15
AI Technical Summary
Existing antibodies targeting WARS1 exhibit cross-reactivity with other aminoacyl-tRNA synthetases (ARSs), limiting their effectiveness in treating infectious diseases.
Development of antibodies and fragments that specifically bind to WARS1 without cross-reactivity, capable of detecting and suppressing WARS1 expression, along with methods for production and use in diagnostic and therapeutic compositions.
The antibodies effectively detect and neutralize WARS1, reducing its expression and associated cytokines, thereby improving diagnostic accuracy and treatment outcomes for infectious diseases.
Smart Images

Figure 0007590791000002 
Figure 0007590791000003 
Figure 0007590791000004
Abstract
Description
[Technical field]
[0001] The present invention relates to an antibody that specifically binds to a WARS protein and uses thereof. [Background technology]
[0002] Aminoacyl-tRNA synthetases (ARSs) are enzymes that mediate the reaction of specifically binding amino acids to tRNAs and play a central role in protein synthesis. In recent years, it has been discovered that these ARSs are involved in various biological phenomena such as apoptosis, angiogenesis, and inflammatory responses in addition to their essential functions. In particular, the general function of human tryptophanyl-tRNA synthetase 1 (WARS1) is to act as an aminoacyl-tRNA synthetase that links tryptophan-recognizing tRNAs for protein synthesis, but a recent interest is the role of WARS1 in host defense mechanisms against infection. The present inventors previously reported that within minutes of infection, monocytes immediately secrete pre-existing WARS1 into the extracellular space without de novo synthesis (Young Ha Ahn. et al. Secreted Tryptophanyl-tRNA Synthetase as a primary defense system against infection. Nature Microbiology 2:16191(2016)).
[0003] By functioning as an endogenous ligand for TLR4 and TLR2, secreted WARS1 activates macrophages and induces innate immune activation. WARS1 also initiates the production of proinflammatory cytokines and chemokines, including TNF-α, IL-6, MIP-1α, IL-8, and IFN-γ, and induces neutrophil infiltration. WARS1 gene expression is then activated by IFN-γ, maintaining the continuous secretion of WARS1. Consistent with these findings, we confirmed that WARS1 is highly elevated in the blood of patients with sepsis, but not in patients with sterile chronic inflammatory disorders, and is secreted regardless of the type of pathogen, including gram-positive and negative bacteria, viruses, and fungi.
[0004] In order to treat infectious inflammatory diseases caused by the above bacteria, viruses and / or fungi, a strategy of developing antibodies against them can be considered; however, since each ARS, including WARS1, has many similarities in protein structure, the antibodies obtained by the immune reaction often do not have high sensitivity and cross-react with other ARSs.
[0005] Therefore, there is a pressing need to develop antibodies that can specifically bind to and effectively neutralize WARS1 without cross-reacting with other ARSs.
[0006] The items described above as background art are intended merely to enhance understanding of the background of the present invention, and should not be considered as prior art already known to those having ordinary skill in the art. Summary of the Invention [Problem to be solved by the invention]
[0007] The present inventors have made extensive efforts to discover an antibody or a fragment thereof that specifically binds to WARS, the expression level of which is significantly increased in patients with infectious diseases such as sepsis. As a result, they have discovered an antibody that specifically binds to WARS, has no cross-reactivity with other ARSs, and has excellent abilities to detect WARS and inhibit its expression, thereby completing the present invention.
[0008] Therefore, an object of the present invention is to provide an antibody or a fragment thereof that specifically binds to tryptophanyl-tRNA synthetase (WARS).
[0009] It is another object of the present invention to provide a polynucleotide encoding said antibody or a fragment thereof.
[0010] It is still another object of the present invention to provide a vector containing the polynucleotide.
[0011] It is still another object of the present invention to provide a cell transformed with said vector.
[0012] Another object of the present invention is to provide a method for producing an antibody or a fragment thereof that specifically binds to WARS, comprising the steps of culturing the cell under conditions in which the polynucleotide is expressed and recovering the polypeptide.
[0013] It is yet another object of the present invention to provide a method for specifically detecting WARS, which comprises the step of contacting the antibody or a fragment thereof, the polynucleotide, the vector or the cell with a sample.
[0014] It is still another object of the present invention to provide a composition for specifically detecting WARS, comprising the antibody or a fragment thereof, a polynucleotide, a vector or a cell.
[0015] It is still another object of the present invention to provide a composition for diagnosing an infectious disease, comprising the antibody or a fragment thereof, a polynucleotide, a vector or a cell.
[0016] It is still another object of the present invention to provide a pharmaceutical composition for preventing or treating an infectious disease, comprising the antibody or a fragment thereof, a polynucleotide, a vector or a cell.
[0017] It is yet another object of the present invention to provide a pharmaceutical composition for preventing or treating an infectious disease, comprising the antibody or a fragment thereof, a polynucleotide, a vector or a cell, and an additional antibiotic.
[0018] Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, the claims and the drawings. [Means for solving the problem]
[0019] According to one aspect, the present invention provides an antibody or a fragment thereof that specifically binds to tryptophanyl-tRNA synthetase (WARS).
[0020] The inventors made efforts to discover an antibody or a fragment thereof that specifically binds to WARS, the expression level of which is significantly increased in patients with infectious diseases such as sepsis, and as a result, discovered an antibody that specifically binds to WARS, has no cross-reactivity with other WARS types, and has excellent ability to detect and inhibit WARS activity.
[0021] As used herein, the term "WARS" refers to tryptophanyl-tRNA synthetase, also known as tryptophan-tRNA ligase, TrpRS, WRS, etc. WARS is an enzyme that mediates the aminoacylation reaction between the amino acid tryptophan and tRNA. In humans, WARS is encoded by the WARS gene, and the amino acid sequence of the protein and the mRNA nucleotide sequence are publicly known under Genbank accession number NP_004175.2 (protein) and Genbank accession number NM_004184.3 (mRNA nucleotide sequence), etc. WARS has two isoforms: a cytoplasmic form (WARS1 or Tryptophanyl-tRNA Synthetase 1, Cytoplasmic) and a mitochondrial form (WARS2 or Tryptophanyl-tRNA Synthetase 2, Mitochondrial).
[0022] According to a preferred embodiment of the present invention, the WARS of the present invention is WARS1.
[0023] As used herein, the term "antibody" is a term of the art and may be used interchangeably herein to refer to a molecule having an antigen-binding site that specifically binds to an antigen. As used herein, the term includes whole antibodies and any fragments (i.e., "antigen-binding portions") or single chains thereof. According to one embodiment of the present invention, an "antibody" refers to a glycoprotein or antigen-binding portion thereof that comprises at least two heavy chains (H) and two light chains (L) interconnected by disulfide bonds. According to another embodiment of the present invention, an "antibody" refers to a single-chain antibody that comprises a single variable region (domain), e.g., a VH domain. Each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region. Generally, the heavy chain constant region comprises three domains, CH1, CH2, and CH3, and each light chain comprises a light chain variable region (abbreviated as VL) and a light chain constant region. The light chain constant region comprises one domain, i.e., CL.
[0024] The VH and VL regions can be further subdivided into hypervariable regions, designated complementarity determining regions (CDRs), which are located between the more conserved regions, designated framework regions (FRs). Each VH and VL is composed of three CDRs and four FRs, which are arranged from the amino-terminus to the carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant regions of the antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.
[0025] As used herein, the term "Fc" refers to the C-terminal region of an antibody heavy chain that mediates binding of an immunoglobulin to host tissues or factors, including binding to Fc receptors located on various cells of the immune system (e.g., effector cells) or the first component (C1q) of the classical complement system. Thus, Fc includes the constant region of an antibody excluding the first constant region immunoglobulin domain (e.g., CH1 or CL). In IgG, IgA, and IgD antibody isotypes, the Fc region includes two identical protein fragments derived from the second (CH2) and third (CH3) constant domains of the antibody's two heavy chains, while IgM and IgE Fc regions include three heavy chain constant domains (CH domains 2-4) in each polypeptide chain. The Fc provided herein can be a native sequence Fc or an Fc variant (e.g., a non-naturally occurring Fc), including any allotypic variant. The Fc may also be an Fc-containing protein polypeptide, such as a "binding protein comprising an Fc region," also referred to as an "Fc fusion protein" (eg, an antibody or immunoconjugate).
[0026] The antibody can have any type (e.g., IgG, IgE, IgM, IgD, IgA, or IgY) or any subclass (e.g., IgG1, IgG2, IgG3, and IgG4 in humans, or IgG1, IgG2a, IgG2b, and IgG3 in mice, etc.) of immunoglobulin molecule. Immunoglobulins, e.g., IgG1, exist in several allotypes that differ from each other in some amino acids. The antibodies disclosed herein may be derived from any one of the commonly known isotypes, types, subclasses, and allotypes. In certain embodiments, the antibodies presented herein belong to the IgG1, IgG2, IgG3, or IgG4 subclass, or any hybrid thereof. In certain embodiments, the antibodies belong to the IgG2, IgG4, or IgG2 / IgG4 subclass.
[0027] Examples of antibodies include naturally occurring or non-naturally occurring antibodies; monoclonal or polyclonal antibodies; chimeric or humanized antibodies; human or non-human antibodies; fully synthetic antibodies; single chain antibodies; monospecific antibodies; and multispecific antibodies (including bi- or trispecific antibodies).
[0028] As used herein, the term "neutralizing antibody" refers to an antibody that neutralizes the biological effects of pathogens or infectious particles when they penetrate the body and protects cells. Neutralizing antibodies are part of the immune response of the acquired immune system against viruses, bacteria, fungi, and microbial toxins. Neutralizing antibodies are produced in a specialized form and bind to the surface structures of infectious particles, achieving immunity by preventing infectious antigens from interacting with host cells.
[0029] In the present specification, the term "fragment" is interpreted to include one or more fragments of an antibody that retains the ability to specifically bind to an antigen, or all forms in which the "one or more fragments of an antibody that retains the ability to specifically bind to an antigen" are linked to other molecules (including a portion of the same or another antibody (such as Fc)). Examples of fragments include a monovalent fragment (Fab fragment) composed of the VL, VH, CL, and CH1 domains; a bivalent fragment (F(ab')2 fragment) containing two Fab fragments linked by a disulfide bridge at the hinge region; an Fd fragment composed of the VH and CH1 domains; an Fv fragment composed of the VL and VH domains of one arm of an antibody and a disulfide-linked Fv (sdFv); a dAb fragment composed of the VH domain; and a combination of an isolated complementarity determining region (CDR) or two or more isolated CDRs that can be selectively linked by a linker. The VL and VH regions may also be linked by a linker to form a single protein chain that pairs to form a monovalent molecule (single-chain Fv (scFv)). Such single-chain antibodies are also included in antibody fragments. The antibodies or antibody fragments also include tetrameric antibodies comprising two heavy chain molecules and two light chain molecules; antibody light chain monomers; antibody heavy chain monomers; antibody light chain dimers; antibody heavy chain dimers; intrabodies; monovalent antibodies; camelid antibodies; and single-domain antibodies (sdAbs).
[0030] According to a preferred embodiment of the present invention, the antibody fragment of the present invention is a fragment selected from the group consisting of Fab, F(ab')2, Fd, sdFv, Fv, dAb, scFv, sdAb and tetramer, or a combined form of said fragment and Fc.
[0031] According to a preferred embodiment of the present invention, the antibody or fragment thereof of the present invention comprises a heavy chain variable region (VH) comprising a heavy chain CDR1 of the third sequence in the sequence listing, a heavy chain CDR2 of the fourth sequence in the sequence listing, and a heavy chain CDR3 of the fifth sequence in the sequence listing.
[0032] According to a preferred embodiment of the present invention, the antibody or fragment thereof of the present invention comprises a light chain variable region (VL) comprising a light chain CDR1 of sequence 6 of the sequence listing, a light chain CDR2 of sequence 7 of the sequence listing, and a light chain CDR3 of sequence 8 of the sequence listing.
[0033] According to a preferred embodiment of the present invention, each antibody (including fragments thereof) composed of the above CDR sequences of the present invention specifically binds to WARS and has no cross-reactivity with other proteins including the ARS family.
[0034] According to a preferred embodiment of the present invention, the antibody or fragment thereof of the present invention comprises a heavy chain variable region (VH) of the first sequence in the sequence listing, and a light chain variable region (VL) of the second sequence in the sequence listing.
[0035] According to a preferred embodiment of the present invention, the antibody or fragment thereof of the present invention comprises one or more sequences selected from the group consisting of the CL sequence of sequence 21 in the sequence listing, the CH1 sequence of sequence 22 in the sequence listing, the hinge sequence of sequence 23 in the sequence listing, the CH2 sequence of sequence 24 in the sequence listing, and the CH3 sequence of sequence 25 in the sequence listing.
[0036] According to a preferred embodiment of the present invention, the antibody or fragment thereof of the present invention comprises all of the CL sequence of sequence 21 in the sequence listing, the CH1 sequence of sequence 22 in the sequence listing, the hinge sequence of sequence 23 in the sequence listing, the CH2 sequence of sequence 24 in the sequence listing, and the CH3 sequence of sequence 25 in the sequence listing.
[0037] According to another aspect of the present invention, there is provided a polynucleotide encoding said antibody or a fragment thereof, a vector comprising said polynucleotide, or a cell transformed with said vector.
[0038] As used herein, the term "polynucleotide" or "nucleic acid molecule" includes DNA molecules and RNA molecules. The polynucleotides or nucleic acid molecules of the present invention may be isolated or recombinant and include single-stranded and double-stranded forms of DNA and RNA, as well as the corresponding complementary sequences. An "isolated nucleic acid" is, in the case of a nucleic acid isolated from a naturally occurring source, a nucleic acid separated from surrounding genetic sequences present in the genome of the individual from whom the nucleic acid is isolated. In the case of a nucleic acid enzymatically or chemically synthesized from a template, e.g., a PCR product, a cDNA molecule, or an oligonucleotide, the nucleic acid produced from such a procedure may be understood to be an isolated nucleic acid molecule. An isolated nucleic acid molecule refers to a nucleic acid molecule in the form of a separate fragment or as a component of a larger nucleic acid construct. A nucleic acid is "operably linked" when it is placed in a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein, the form in which the polypeptide is secreted; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the polypeptide sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are located contiguous, and, in the case of a secretory leader, contiguous and in the same reading frame. Enhancers, however, need not be located contiguous. Linking is accomplished by ligation at convenient restriction enzyme sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
[0039] As used herein, the term "vector" refers to a vehicle into which a polynucleotide sequence can be inserted for introduction into a cell capable of replicating said polynucleotide sequence. The polynucleotide sequence can be exogenous or heterologous. Vectors can include, but are not limited to, plasmids, cosmid vectors, and viral vectors (such as retroviruses, adenoviruses, and adeno-associated virus vectors). Those skilled in the art can construct vectors by standard recombinant techniques (e.g., Maniatis, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY, 1988; and Ausubel et al., In: Current Protocols in Molecular Biology, John, Wiley & Sons, Inc, NY, 1994).
[0040] As used herein, the term "expression vector" refers to a vector that contains a nucleotide sequence that codes for at least a portion of a gene product to be transcribed. In some cases, the RNA molecule is then translated into a protein, polypeptide, or peptide. Expression vectors can contain a variety of regulatory sequences. Along with regulatory sequences that control transcription and translation, vectors and expression vectors can also contain nucleic acid sequences that provide other functions.
[0041] As used herein, the term "cell" refers to any transformable cell, including eukaryotic and prokaryotic cells, that can replicate the vector and express the gene encoded by the vector. A cell may be transfected, transduced, or transformed by the vector, which refers to the process by which an exogenous polynucleotide (nucleic acid molecule) is transferred or introduced into a host cell. As used herein, the term "transformation" is used to include the above terms "transfected" and "transduced."
[0042] The (host) cells of the present invention are preferably, but not limited to, bacterial cells, insect cells, or mammalian cells, more preferably, in the case of insect cells, Sf9, and in the case of mammalian cells, HEK293 cells, HeLa cells, ARPE-19 cells, RPE-1 cells, HepG2 cells, Hep3B cells, Huh-7 cells, C8D1a cells, Neuro2A cells, CHO cells, MES13 cells, BHK-21 cells, COS7 cells, COP5 cells, A549 cells, MCF-7 cells, HC70 cells, HCC1428 cells, BT-549 cells, PC3 cells, LNCaP cells, Capan-1 cells, Panc-1 cells, MIA cells, and the like. PaCa-2 cells, SW480 cells, HCT166 cells, LoVo cells, A172 cells, MKN-45 cells, MKN-74 cells, Kato-III cells, NCI-N87 cells, HT-144 cells, SK-MEL-2 cells, SH-SY5Y cells, C6 cells, HT-22 cells, PC-12 cells, NIH3T3 cells, etc. can be used.
[0043] The (host) cells of the present invention are preferably cells that exclude embryonic stem cells.
[0044] According to a preferred embodiment of the present invention, the host cell of the present invention is an isolated or separated host cell.
[0045] According to yet another aspect of the present invention, there is provided a method for producing an antibody or fragment thereof that specifically binds to WARS, comprising the steps of culturing the cell under conditions in which the polynucleotide is expressed and recovering the polypeptide.
[0046] Among the contents of the production method of the present invention, the antibody or a fragment thereof, the nucleotide, the vector, the cell, etc. are as described above. The polypeptide of the production method may be or contain the antibody or a fragment thereof (antigen-binding fragment) of the present invention.
[0047] According to a preferred embodiment, the present invention includes the steps of: (a) transforming a host cell with an expression vector (recombinant expression vector) containing the polynucleotide; (b) culturing the transformed host cell to produce an antibody or a fragment thereof; and (c) obtaining the antibody or a fragment thereof produced in the host cell.
[0048] According to yet another aspect of the present invention, there is provided a method for specifically detecting WARS, comprising the step of contacting the antibody or a fragment thereof, the polynucleotide, the vector or the cell with a sample.
[0049] In yet another aspect, the present invention provides a composition for specifically detecting WARS, comprising the antibody or a fragment thereof, a polynucleotide, a vector, or a cell.
[0050] The antibodies or fragments thereof of the present invention specifically bind to WARS and are therefore useful in diagnostic assays to detect and quantitate the expression of WARS protein in, for example, specific cells, tissues, or serum.
[0051] As used herein, the term "sample" may refer to cells, tissues, blood, whole blood, serum, plasma, cerebrospinal fluid, etc., collected from a subject (e.g., a subject for which the presence or absence of an infectious disease or infectious complications is to be diagnosed). Methods for detecting proteins using the antibodies or fragments thereof, polynucleotides, vectors, or cells include, but are not limited to, Western blot, immunoblot, dot blot, immunohistochemistry, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay, competitive binding analysis, immunoprecipitation, etc.
[0052] In yet another aspect, the present invention provides a composition for diagnosing an infectious disease, comprising the antibody or fragment thereof, polynucleotide, vector or cell.
[0053] In yet another aspect, the present invention provides a diagnostic kit for an infectious disease comprising the antibody or fragment thereof, polynucleotide, vector or cell.
[0054] In yet another aspect, the present invention provides a pharmaceutical composition for preventing or treating an infectious disease, comprising the antibody or a fragment thereof, a polynucleotide, a vector or a cell.
[0055] In yet another aspect, the present invention provides a pharmaceutical composition for treating a disease caused by overexpression of WARS, comprising the antibody or a fragment thereof, a polynucleotide, a vector or a cell.
[0056] Among the contents of the diagnostic composition or pharmaceutical composition of the present invention, the antibody or a fragment thereof, the nucleotide, the vector, the cell, etc. are as described above.
[0057] The diseases to be prevented, ameliorated or treated by the present invention are not limited, but preferably include all diseases associated with the expression or activity of WARS.
[0058] The diseases associated with the expression or activity of WARS preferably include, but are not limited to, infectious diseases.
[0059] It has been reported that the expression level of WARS increases rapidly from the early stage of infection with bacteria, viruses, fungi, etc., and when symptoms such as pneumonia and sepsis appear as infectious complications, it increases significantly more than in normal control groups. Furthermore, in patients with sepsis, the expression level of WARS is highly correlated with the severity and prognosis of sepsis, and since WARS increases only in infectious inflammation, it can quickly and accurately distinguish infectious inflammatory diseases from non-infectious inflammatory diseases, and is highly valuable as a diagnostic marker for new infectious diseases and infectious complications. In particular, the amount of WARS is significantly increased in the serum of patients with sepsis or septic shock due to bacterial or fungal infection compared to the serum of healthy normal control groups, and there is no statistically significant difference in the increasing trend of WARS between patients with sepsis due to gram-negative bacteria, gram-positive bacteria, and fungal infection, so that WARS can be usefully used in the diagnosis of sepsis due to gram-negative bacteria, gram-positive bacteria, or fungal infection. In addition, the level of WARS is more increased in patients with septic shock than in patients with sepsis, and the expression level of WARS is also associated with the severity of sepsis. That is, the higher the expression level of WARS, the more severe the symptoms of sepsis can be determined (Korean Patent Publication No. 10-2017-0027313). That is, by using the WARS-specific antibody of the present invention, the expression level of WARS in a biological sample can be detected with high accuracy, thereby providing information useful for diagnosing infectious diseases or infectious complications and predicting their prognosis.
[0060] The antibody or fragment thereof according to the present invention may be provided as an analytical kit or diagnostic kit. The type of the kit is not particularly limited as long as it is known in the art as an analytical kit that provides an antibody or a peptide having a specific binding domain as a component, and includes, for example, Western blot, ELISA, radioimmunoassay, radial immunodiffusion, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, tissue immunostaining, immunoprecipitation analysis, complement fixation analysis, FACS, or protein chip kits.
[0061] Infectious diseases of the present invention include, but are not limited to, pneumonia, pulmonary tuberculosis, tuberculosis, sepsis, septic shock, salmonellosis, food poisoning, typhoid fever, urinary tract infection, cystitis, pyelonephritis, urethritis, prostatitis, upper respiratory tract infection, otitis media, and viral infectious diseases such as AIDS virus and coronavirus.
[0062] The coronaviruses include, but are not limited to, severe acute respiratory syndrome virus (SARS-CoV), Middle East respiratory syndrome virus (MERS-CoV), SARS-CoV-2, the cause of COVID-19 (coronavirus disease 19), infectious bronchitis virus (IBV), transmissible gastroenteritis virus (TGE), porcine epidemic diarrhea virus (PED), bovine coronavirus (BCoV), feline / canine coronavirus (FCoV / CCoV), mouse hepatitis virus (MHV), and the like.
[0063] According to a preferred embodiment, the infectious disease is an infectious inflammatory disease.
[0064] Infectious inflammatory diseases are infectious diseases accompanied by inflammation, and the desired therapeutic effect can be achieved by suppressing the proliferation of pathogens causing the infection (viruses, bacteria, fungi, etc.) or regulating the inflammation.
[0065] According to a preferred embodiment, the infectious inflammatory disease is sepsis or septic shock.
[0066] The sepsis includes, but is not limited to, early sepsis, severe sepsis, septic shock, and sepsis-associated multiple organ dysfunction syndrome (MODS), disseminated intravascular coagulation syndrome (DIC), acute respiratory distress syndrome (ARDS), or acute kidney injury (AKI).
[0067] The composition of the present invention has the advantages of not only being able to detect WARS with high sensitivity, but also being able to significantly reduce the amount of WARS increased by infection and to reduce the expression of inflammatory cytokines (e.g., IL-8, IL-6, MIP-1α, TNF-α, etc.), thereby achieving both diagnosis and treatment at the same time.
[0068] As used herein, the term "cytokine" refers to a protein immunoregulator secreted from immune cells, and is used in a sense including chemokines.
[0069] The cytokines include IL-8, IL-6, MIP-1α, INF-γ, TNF-α, IL-1β, IL-10, and the like.
[0070] According to a preferred embodiment of the present invention, the pharmaceutical composition comprises a pharma- ceutically acceptable carrier.
[0071] According to a preferred embodiment, the pharmaceutical composition of the present invention comprises the antibody or a fragment thereof, a polynucleotide, a vector or a cell, and an additional antibiotic.
[0072] The antibiotics preferably include, but are not limited to, Gentamycin, Ampicillin, Kanamycin, Chloramphenicol, Streptomycin, Tetracycline, Erythromycin, Vancomycin, Penicillin, Spectinomycin, Chloramphenicol, Sulfadiazine, and Trimethoprim.
[0073] According to one embodiment of the present invention, the survival rate of individuals with infectious diseases can be increased by administering the WARS-specific antibody of the present invention one or more times after administration of an antibiotic, or by administering it in combination with an antibiotic, or by administering the antibody followed by administration of an antibiotic.
[0074] The pharma- ceutically acceptable carriers contained in the pharmaceutical composition of the present invention are those commonly used in formulation, including, but not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition to the above components, the pharmaceutical composition of the present invention may further include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc. Suitable pharma- ceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).
[0075] The pharmaceutical composition of the present invention can be administered orally or parenterally, and is preferably administered parenterally, for example, by intravenous injection, transdermal administration, subcutaneous injection, intramuscular injection, intravitreal injection, subretinal injection, suprachoroidal injection, eye drop administration, intraventricular injection, intrathecal injection, intraamniotic injection, intraarterial injection, intraarticular injection, intracardiac injection, intracavernous injection, intracerebral injection, intracisternal injection, intracoronary ... Injection), Intracranial Injection, Intradural Injection, Epidural Injection, Intrahippocampal Injection, Intranasal Injection, Intraosseous Injection, Intraperitoneal Injection, Intrapleural Injection Injection, Intraspinal Injection, Intrathoracic Injection, Intrathymic Injection, Intrauterine Injection, Intravaginal Injection, Intraventricular Injection, Intravesical Injection, SubconjunctivalThe compound can be administered by intratumoral injection, intratumoral injection, local injection, intraperitoneal injection, and the like.
[0076] The appropriate dosage of the pharmaceutical composition of the present invention varies depending on various factors such as the formulation method, administration method, age, weight, sex, pathological condition, diet, administration time, administration route, excretion rate and reaction sensitivity of the patient, and a doctor of ordinary skill can easily determine and prescribe an effective dosage for the desired treatment or prevention.
[0077] The composition of the present invention may be administered in a pharmaceutically effective amount to a subject for diagnosis, prevention, improvement, or treatment. The term "pharmaceutically effective amount" refers to an amount that shows a higher response than a negative control group. The total effective amount of the antibody or fragment thereof of the present invention may be administered to a patient in a single dose, or may be administered in multiple doses over a long period of time in a fractionated treatment protocol. The daily dose of the antibody or fragment thereof of the present invention to a human body is generally 0.0001 to 100 mg / kg. However, the effective dose of the antibody or fragment thereof of the present invention is determined in consideration of various factors such as the age, weight, health condition, sex, severity of the disease, diet, and excretion rate of the patient, as well as the administration route and number of treatments of the pharmaceutical composition. Taking these points into consideration, a person having ordinary skill in the art can determine an appropriate effective dose of the antibody or fragment thereof of the present invention according to a specific use of the present invention.
[0078] The pharmaceutical composition of the present invention may be prepared in the form of a unit dose by formulating it with pharma- ceutically acceptable carriers and / or excipients, or may be prepared in a multi-dose container, by a method that can be easily carried out by a person having ordinary skill in the art to which the present invention pertains. In this case, the dosage form may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or in the form of an extract, powder, granules, tablets or capsules, and may further include a dispersant or stabilizer.
[0079] In yet another aspect, the present invention provides the antibody or a fragment thereof, polynucleotide, vector or cell for use in therapy.
[0080] In yet another aspect, the present invention provides a method for treating a disease, comprising administering to a subject an effective amount of the antibody or fragment thereof, polynucleotide, vector or cell.
[0081] In the present invention, the term "subject" refers to an individual to which the composition of the present invention should be administered, and includes, without limitation, mammals, birds, insects, amphibians, fish, and the like.
[0082] According to a preferred embodiment, the method of the present invention further comprises the step of administering an antibiotic.
[0083] According to a preferred embodiment, the therapeutic method of the present invention comprises administering the antibody or a fragment thereof, polynucleotide, vector or cell simultaneously with an antibiotic, before administration of the antibiotic, or after administration of the antibiotic one or more times.
[0084] The antibiotics preferably include, but are not limited to, gentamicin, ampicillin, kanamycin, chloramphenicol, streptomycin, tetracycline, erythromycin, vancomycin, penicillin, spectinomycin, chloramphenicol, sulfadiazine, and trimethoprim.
[0085] According to one embodiment of the present invention, the survival rate of individuals with infectious diseases can be increased by administering the WARS-specific antibody of the present invention one or more times after administration of an antibiotic, or by administering it in combination with an antibiotic, or by administering the antibody followed by administration of an antibiotic. Effect of the Invention
[0086] The features and advantages of the present invention can be summarized as follows: (i) The present invention provides an antibody or a fragment thereof that specifically binds to tryptophanyl-tRNA synthetase (WARS). (ii) The antibody or fragment thereof of the present invention has an excellent ability to specifically bind to WARS, has no cross-reactivity with other ARSs, and has excellent ability to detect WARS and inhibit its activity, and therefore can be effectively used for the diagnosis and / or treatment of infectious diseases. [Brief description of the drawings]
[0087] [Figure 1a] Schematic diagram of the vectors used to convert GKB101 into an IgG antibody: Figure 1a shows the heavy chain vector and Figure 1b shows the light chain vector. [Figure 1b] See column in Figure 1a. [Figure 2a] 2A shows the results of measuring the target binding strength of GKB101, in which FIG 2A shows the results of measuring the binding strength of GKB101 to human and mouse WARS1 using GE Biacore T200, and FIG 2B shows the results of measuring absorbance by ELISA. [Figure 2b] See column Figure 2a. [Figure 3a] 3 shows the results of in vitro neutralizing activity verification using GKB101, in which Fig. 3a shows the results of reducing the secretion of TNF-α, and Fig. 3b shows the results of reducing the secretion of mCXCL2 (a homologue of human IL-8). [Figure 3b] See column Figure 3a. [Figure 4a]These are diagrams showing the effect of WARS1-specific antibodies on the survival rate of mice infected with bacteria. FIG. 4a shows the results of analyzing survival rates after injecting PBS or GKB101 into mice that had been injected with CS (cecal slurry) into their peritoneal cavity to induce severe sepsis. FIG. 4b and FIG. 4c show the results of confirming that the administration of GKB101 reduces the concentration of WARS1 (FIG. 4b: plasma, FIG. 4c: peritoneal fluid). FIG. 4d to FIG. 4g show the results of confirming that the administration of GKB101 reduces the concentrations of IL-8 (FIG. 4e), IL-6 (FIG. 4f), MIP-1α (FIG. 4d), and TNF-α (FIG. 4g) secreted into the peritoneal fluid. Figures 4h to 4k show the results confirming that administration of GKB101 resulted in a relative decrease in the concentrations of ALT (Figure 4h), AST (Figure 4i), BUN (Figure 4j), and creatinine (Figure 4k) (circles represent the normal group; squares represent the PBS group; triangles represent the GKB101 group). [Figure 4b] See column Figure 4a. [Figure 4c] See column Figure 4a. [Figure 4d] See column Figure 4a. [Figure 4e] See column Figure 4a. [Figure 4f] See column Figure 4a. [Figure 4g] See column Figure 4a. [Figure 4h] See column Figure 4a. [Figure 4i] See column Figure 4a. [Figure 4j] See column Figure 4a. [Figure 4k] See column Figure 4a. [Figure 5a]Figure 5 shows the effect of WARS1 specific antibody on the survival rate of mice infected with bacteria. Figure 5a shows the survival rate of mice after injecting isotype IgG or GKB101 into the peritoneal cavity of mice with severe sepsis induced by injecting CS (Cecal slurry) into the peritoneal cavity. Figures 5b and 5c show the results of confirming that the administration of GKB101 reduces the concentration of WARS1 (Figure 5b: plasma, Figure 5c: peritoneal fluid). Figures 5d to 5g show the results of confirming that the administration of GKB101 reduces the concentrations of IL-8 (Figure 5e), IL-6 (Figure 5f), MIP-1α (Figure 5d), and TNF-α (Figure 5g) secreted into the peritoneal fluid. Figures 5i to 5k show the results of confirming that the administration of GKB101 reduces the concentrations of ALT (Figure 5h), AST (Figure 5i), BUN (Figure 5j), and creatinine (Figure 5k) relatively. [Figure 5b] See column Figure 5a. [Figure 5c] See column Figure 5a. [Figure 5d] See column Figure 5a. [Figure 5e] See column Figure 5a. [Figure 5f] See column Figure 5a. [Figure 5g] See column Figure 5a. [Figure 5h] See column Figure 5a. [Figure 5i] See column Figure 5a. [Figure 5j] See column Figure 5a. [Figure 5k] See column Figure 5a. [Figure 6a] 6A and 6B are diagrams showing the results of examining the combined effect of GKB101 and antibiotics using a mouse model of severe sepsis, in which Fig. 6A shows the injection schedule of gentamicin and GKB101, and Fig. 6B shows a graph of survival rate over time after injection of gentamicin and GKB101. [Figure 6b] See column Figure 6a. [Figure 7a]This is a diagram showing the results of verifying the efficacy of GKB101 using an endotoxemia model in marmosets. Figure 7a shows the injection schedule of PBS and GKB101, and Figures 7b to 7e show the changes in body temperature (Figure 7b), body weight (Figure 7c), WBC in blood (Figure 7d), and neutrophils (Figure 7e) over time in the PBS or GKB101 administration group after LPS induction. Figure 7f shows the level of WARS1 in plasma after administration of GKB101, and Figure 7g shows the results of measuring the level of TNF-α. [Figure 7b] See column Figure 7a. [Figure 7c] See column Figure 7a. [Figure 7d] See column Figure 7a. [Figure 7e] See column Figure 7a. [Figure 7f] See column Figure 7a. [Figure 7g] See column Figure 7a. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0088] The present invention will be described in more detail with reference to the following examples. It will be obvious to those skilled in the art that these examples are merely for the purpose of illustrating the present invention in more detail, and that the scope of the present invention is not limited by these examples in accordance with the gist of the present invention. EXAMPLES
[0089] Example 1. Conversion of scFv antibodies to IgG1 antibodies As an scFv antibody that specifically binds to WARS1 (sequence 26 of the sequence listing), an scFv antibody was selected that includes a heavy chain variable region (sequence 1 of the sequence listing) including heavy chain CDR1 (sequence 3 of the sequence listing), heavy chain CDR2 (sequence 4 of the sequence listing), and heavy chain CDR3 (sequence 5 of the sequence listing), and a light chain variable region (sequence 2 of the sequence listing) including light chain CDR1 (sequence 6 of the sequence listing), light chain CDR2 (sequence 7 of the sequence listing), and light chain CDR3 (sequence 8 of the sequence listing). The selected scFv antibody was inserted into a heavy chain vector (Figure 1a) and a light chain vector (Figure 1b) to clone a plasmid DNA vector. First, a polynucleotide encoding scFv was amplified by PCR. The base sequences of the primers used to amplify the gene of the CDR region of the scFv are as follows: Forward (gtggccacagcggccgatgtccactcggaagtacagttggtcgaaagtggc, 9th sequence in the sequence listing), Reverse (gaagaccgatgggcccttggtgctagccgatgagacggtcactaaagtgcc, 10th sequence in the sequence listing).
[0090] The nucleotide sequences of the primers used to amplify the gene for the VL region of scFv are as follows: Forward (gccacagcggccgatgtccactcggacattcaaatgacgcagagtccctc, 11th sequence in the sequence listing); reverse (gaagacagatggtgcagccacagatcttttaatttccactttagttccctgcc, 12th sequence in the sequence listing).
[0091] The IgG conversion method used to prepare a monoclonal antibody (hereinafter, named GKB101) using the scFv antibody was as follows:
[0092] The heavy and light chain genes for IgG conversion of GKB101 were amplified using pOptiVEC and pcDNA 3.3, parent vectors expressing Herceptin (Figures 1a and 1b). The primer sequences used to amplify the CH (VH3-23) and CL region genes are as follows: CH forward (ggcactttagtgaccgtctcatcggctagcaccaagggcccatcggtcttc, 13th sequence in the sequence listing); CH reverse (gccactttcgaccaactgtacttccgagtggacatcggccgctgtggccac, 14th sequence in the sequence listing); CL forward (ggcagggaactaaagtggaaattaaaagatctgtggctgcaccatctgtcttc, 15th sequence in the sequence listing); CL reverse (gagggactctgcgtcatttgaatgtccgagtggacatcggccgctgtggc, 16th sequence in the sequence listing).
[0093] Fab2 (VH-1-69) for IgG conversion of GKB101 was amplified by PCR, and VH1-69_Forward (gtggccacagcggccgatgtccactcgcaagttcagctggtccagagcggc, sequence no. 17 in the sequence listing) and VH1-69_Reverse (gaagaccgatgggcccttggtgctagccgatgagacggtaaccagagtaccc, sequence no. 18 in the sequence listing) were used as inserts, and CH1-69_Forward (gccgctctggaccagctgaacttgcgagtggacatcggccgctgtggccacc, sequence no. 19 in the sequence listing) and CH1-69_Reverse (gggtactctggttaccgtctcatcggctagcaccaagggcccatcggtcttc, sequence no. 20 in the sequence listing) were used as vectors.
[0094] Each vector template (pcDNA3.3-Herceptin_CL, pOptiVEC-Herceptin_CH) and insert template (scFv, Fab phage vector) were subjected to PCR using the primers (10 pmol each) under the conditions of 95°C / 3 min; 95°C / 30 sec, 60°C / 30 sec, 72°C / 30 sec, 30 cycles; 72°C / 5 min to amplify the VH and VL of GKB101 for GKB101 conversion, and the CH, CL and VH 1-69 genes of the Herceptin expression vector. The PCR products were inserted into a vector used for IgG production using DpnI restriction enzyme. The vectors containing DNA encoding the light and heavy chains of IgG containing the variable region of scFv prepared above were co-transformed into Expi293F cells to allow co-expression of the light and heavy chains in the cells.
[0095] Example 2. Transient transfection and separation and purification using a column For protein purification through the transient expression system, ExpiHEK293 (Thermofisher) cell line and Freestype293 expression media (Thermofisher) were used. For transfection, Expifectamine 293 (Thermofisher) reagent and plasmid DNA with a 1:1 ratio of GKB101 heavy and light chains were used. After transfection, the cells were cultured with shaking for about 5 days, and the cell culture medium was centrifuged to collect only the supernatant, which was used for protein isolation and purification. The collected supernatant was loaded onto a Hitrap MabselectSure column (GE Healthcare Life Sciences), washed with PBS to remove non-specific binding, and proteins that specifically bound to the column were primarily isolated using 100 mM citrate buffer (pH 3.0) + 50 mM NaCl. The eluate obtained by FPLC was loaded onto size exclusion chromatography (GE Healthcare Life Sciences) to obtain highly pure GKB101. The final yield of GKB101 obtained through the optimized conditions of the transient expression system was 37 mg in total based on 500 ml of cell culture medium, and the endotoxin level was 0.002 EU / g.
[0096] The sequence of the GKB101 antibody prepared through the above process is as follows: [Table 1]
[0097] Example 3. Measurement of target binding strength of GKB101 1) SPR: Binding strength was measured using a Series S Sensor CM5 chip (GE Healthcare Life Sciences) and a GE Bioacore T200. HBS-EP (GE Healthcare Life Sciences) was used as the buffer, and serial dilutions of GKB101 or buffer were injected at a flow rate of 30 μl / min for 1 to 10 minutes, followed by washing with the analyte for 20 minutes.
[0098] 2) ELISA: GKB101 was coated onto a 96-well plate (Maxisorp, Thermofisher) at a concentration of 1 μg / ml and then blocked with PBS containing 1% BSA at room temperature for 1 hour. Recombinant WARS1 protein was diluted in a concentration-dependent manner and added to each coated well, reacted at room temperature for 1 hour, and then washed 4 times with PBST (PBS + Tween 20). Anti-WARS1 antibody (Abfrontier) was added to each well and reacted at room temperature for 1 hour, and then washed 4 times with PBST. Secondary antibody conjugated with HRP (anti-Human IgG, cell-signaling) was reacted for 1 hour and then washed with PBST. After color development with TMB substrate (BD), absorbance was measured at 490 nm (VersaMax Microplate reader).
[0099] 3) Immunoblot: 20 ng each of WARS1 human and mouse recombinant proteins and 30 μg each of cell culture supernatants from human mononuclear cell line THP-1 and mouse macrophage cell line J774.1A stimulated with LPS for 24 hours were loaded onto 8% SDS-PAGE and then transferred to a PVDF membrane (Millipore). The membrane was reacted with 1 μg / ml GKB101 for 1 hour and then washed three times with TBST (TBS + Tween 20). The secondary antibody (anti-human IgG HRP, Millipore) was reacted for 1 hour and then washed three times with TBST. Then, ECL (Western (R)Color was developed using bright ECL (Advanta) (LAS-4000, Fujifilm).
[0100] 4) Results: The binding affinity of GKB101 to recombinant WARS1 protein was measured and compared. It showed strong binding affinity to human WARS1 in both ELISA and SPR, with a binding affinity of approximately 0.2 nM to human recombinant protein and approximately 3.76 nM to mouse recombinant protein (Fig. 2a). In addition, in immunoblotting experiments, WARS1 in the culture supernatant of human monocytes and mouse macrophage cell lines, as well as recombinant protein, was effectively detected through GKB101 (Fig. 2b).
[0101] Example 4. Verification of neutralizing activity of WARS1-specific antibodies in vitro To investigate whether the WARS1-specific antibody GKB101 has neutralizing activity in vitro, an experiment was carried out using the mouse macrophage cell line J774.1A. The culture medium for mouse macrophages was high glucose DMEM (Gibco) with 10% FBS and 1% penicillin-streptomycin. One day before, 8 × 10 cells were cultured per well in a 48-well cell culture plate (Nunc). 4 After plating the number of cells, the cells were plated in plain DMEM 2 hours before treating the cells with the antigen-antibody mixture. Recombinant protein WARS1 200nM and GKB101 were mixed at different concentrations and mixed for 2 hours in a 37℃ incubator, after which the mixture was added to each well containing cells. After about 15 hours, the culture medium was centrifuged to obtain the supernatant, which was used to measure CXCL2 (R&D) and TNF-α (Biolegend). ELISA was performed according to the methodology of each manufacturer.
[0102] In mouse macrophages, GKB101 significantly decreased TNF-α secretion at molar ratios of 1:2.5 and 1:5 to 200 nM WARS1 (Fig. 3a). mCXCL2 (mouse IL-8 homolog) showed a tendency to decrease at 1:5 and 1:2.5, with a statistically significant difference at 1:2.5 (Fig. 3b). All results were analyzed using the ANOVA statistical program.
[0103] Example 5. Effect of WARS1-specific antibodies on survival rate of mice infected with bacteria Mice were injected with CS to induce severe sepsis, and then PBS or GKB101 was injected intravenously twice at 2.5 mg / kg, either 4 or 20 hours after CS injection, and survival analysis was performed up to 60 hours.
[0104] WARS1 and cytokine analysis: To confirm the neutralizing ability of GKB101 to WARS1, peritoneal fluid and blood were collected at 5, 11, 18, and 20 hours, and WARS1 (in house), TNF-α (Biolegend), MIP-1α (R&D), mIL-6 (Biolegend), and mCXCL2 (IL-8 homolog, R&D) were measured by ELISA. Cytokine ELSIA, except for WARS1, was performed according to the methodology of each manufacturer. WARS1 was measured as follows: GKB101 was coated on a 96-well plate (Maxisorp, Thermofisher) at a concentration of 1 μg / ml, and then blocked with PBS containing 1% BSA at room temperature for 1 hour. Plasma, peritoneal fluid samples, and standards containing diluted recombinant mouse recombinant proteins were placed in the blocked wells, reacted at room temperature for 1 hour, and then washed four times with PBST (PBS + Tween 20). Anti-WARS1 antibody (Abfrontier) was added to each well and incubated at room temperature for 1 hour, then washed 4 times with PBST. Secondary antibody with HRP (anti-Human IgG, cell-signaling) was incubated for 1 hour, then washed with PBST. After color development with TMB substrate (BD), absorbance was measured at 490 nm (VersaMax Microplate reader).
[0105] Blood biochemical test: A portion of the blood was injected into a vacutainer containing a clot activator and left at room temperature for 10 to 15 minutes to clot. Then, the blood was centrifuged at 3000 rpm for 10 minutes to obtain serum, which was used to measure AST (aspartate aminotransferase), ALT (alanin aminotransferase), BUN (blood urea nitrogen), and creatinine using a blood biochemistry analyzer (7180 Hitachi, Japan).
[0106] To confirm the effect of GKB101 on the survival rate of mice, animal experiments using mice were conducted according to the experimental outline in Figure 4a, and survival analysis was performed. CS (Cecal slurry) was injected into the abdominal cavity of mice, and PBS or GKB101 was injected intravenously into the mice after inducing severe sepsis at 4 and 20 hours, respectively. The survival rate of the mice was observed up to 60 hours after infection. As a result, the survival rate of CS+PBS (PBS injection after induction of severe sepsis) was 50% at 29 hours and 20% at 41 hours, while the survival rate of CS+GKB101 (GKB101 injection after induction of severe sepsis) was 80% at 29 hours and 50% at 41 hours, which was higher than that of PBS. The concentration of WARS1 was significantly decreased by GKB101 in the peritoneal fluid (Fig. 4c) and plasma (Fig. 4b) at 11 or 18 hours, and the levels of IL-8 (Fig. 4e), IL-6 (Fig. 4f), MIP-1α (Fig. 4d), and TNF-α (Fig. 4g) secreted into the peritoneal fluid were also significantly decreased at 11 or 18 hours. ALT (Fig. 4h), AST (Fig. 4i), BUN (Fig. 4j), and creatinine (Fig. 4k) tended to decrease relatively, and ALT and BUN tended to decrease significantly in the GKB101-injected group compared to the PBS-injected group at 11 hours. All results were analyzed using an ANOVA statistical program (*, P<0.05; **, P<0.01; ***, P<0.001).
[0107] Example 6. Effect of WARS1-specific antibodies on survival rate of mice infected with bacteria 2 After injecting CS into mice to induce severe sepsis, isotype IgG or GKB101 was injected ip three times at 5 mg / kg, 2.5 mg / kg, 2.5 mg / kg at 4 h, 8 h, and 12 h, respectively, and at 10 mg / kg per mouse, and survival analysis was performed up to 72 h.
[0108] WARS1 and cytokine analysis: To confirm the neutralizing ability of GKB101 to WARS1, peritoneal fluid and blood were collected 2 hours after intraperitoneal injection, 6 hours, 10 hours, and 14 hours later, and WARS1 (in house), TNF-α (Biolegend), MIP-1α (R&D), mIL-6 (Biolegend), and mCXCL2 (IL-8 homolog, R&D) were measured by ELISA. Cytokine ELSIA, except for WARS1, was performed according to the methodology of each manufacturer. WARS1 was measured as follows: GKB101 was coated on a 96-well plate (Maxisorp, Thermofisher) at a concentration of 1 μg / ml, and then blocked with PBS containing 1% BSA at room temperature for 1 hour. Plasma, peritoneal fluid samples, and diluted recombinant mouse recombinant protein standards were added to the blocked wells and incubated at room temperature for 1 hour, then washed 4 times with PBST (PBS+Tween20). Anti-WARS1 antibody (Abfrontier) was added to each well and incubated at room temperature for 1 hour, then washed 4 times with PBST. Secondary antibody conjugated with HRP (anti-Human IgG, cell-signaling) was incubated for 1 hour, then washed with PBST. After color development with TMB substrate (BD), absorbance was measured at 490 nm (VersaMax Microplate reader).
[0109] To confirm the effect of GKB101 on the survival rate of mice, animal experiments using mice were performed according to the experimental outline in Figure 5a, and survival analysis was performed. CS (Cecal slurry) was injected into the abdominal cavity of mice, and severe sepsis was induced in the mice. Isotype IgG or GKB101 was injected intraperitoneally at 4, 8, and 12 hours, respectively. The survival rate of the mice was observed up to 72 hours after infection. As a result, the survival rate of CS + isotype IgG (isotype IgG injection after induction of severe sepsis) was 20% at 28 hours and 10% at 36 hours, while the survival rate of CS + GKB101 (GKB101 injection after induction of severe sepsis) was 80% at 28 hours and 70% at 36 hours, which was significantly higher than that of isotype IgG (Figure 5a). The concentration of WARS1 was decreased by GKB101 in peritoneal fluid (Fig. 5c) and plasma (Fig. 5b) at 6, 10, and 14 hours. IL-8 (Fig. 5e), IL-6 (Fig. 5f), MIP-1α (Fig. 5d), and TNF-α (Fig. 5g) secreted into the peritoneal fluid also tended to decrease after GKB101 injection, especially at 14 hours, IL-8, MIP-1α, and TNF-α were significantly decreased. ALT (Fig. 5h), AST (Fig. 5i), BUN (Fig. 5j), and creatinine (Fig. 5k) tended to decrease relatively, and ALT and BUN at 14 hours tended to decrease significantly in the GKB101-injected group compared to isotype IgG. All results were analyzed using an ANOVA statistical program (*, P<0.05; **, P<0.01; ***, P<0.001).
[0110] Example 7. Effect of WARS1-specific antibodies and antibiotics on survival rate of mice infected with bacteria After CS injection and administration of antibiotics (gentamicin) to mice with severe sepsis, isotype IgG or GKB101 was injected iv at 5 mg / kg, 2.5 mg / kg, 2.5 mg / kg, and 10 mg / kg per mouse at 4, 8, or 20 h, respectively, and survival analysis was performed up to 72 h.
[0111] Analysis of the survival rate of CS-induced mice treated with GKB101 and antibiotics showed that the survival rate of the GKB101-treated group was 80% at 24 hours and 70% at 72 hours, showing a significant difference from that of the isotype IgG-treated group. All results were analyzed using an ANOVA statistical program (Figure 6).
[0112] Example 8. Verification of efficacy of GKB101 using an endotoxemia model in marmosets Marmosets (Callithrix jacchus) were obtained from the Experimental Animal Center of the Osong Foundation for Advanced Medical Industry Promotion (Chungbuk, Republic of Korea). All common marmosets were housed in stainless steel cages. In the SPF animal facility, under conditions of 12-h dawn and 12-h dusk at a temperature of 27 ± 2 °C and humidity of 30% to 70%, common marmosets were provided with standard marmoset chow (Non-human primate-maintenance, Altromin, Lage, Germany) and water ad libitum. All protocols were approved by the Animal Protection Committee of the Experimental Animal Center of the Osong Foundation for Advanced Medical Industry Promotion. After injecting LPS into marmosets to induce endotoxemia, PBS or GKB101 was injected iv twice at 0.2 h and 2 h at a total of 2 mg / kg, and then observed for 24 h.
[0113] The number of immune cells in the blood of marmoset endotoxemia model was confirmed, and the group administered anti-WARS1 antibody showed a significant increase in WBC and neutrophils at 12 hours (*, P<0.05, **, P<0.01). In addition, the effect of GKB101 administration on the expression of WARS1, cytokines, and chemokines in blood was compared. In the experimental group administered GKB101, an anti-WARS1 antibody in blood proteins, WARS1 was significantly decreased at 0.5 hours, 1 hour, 2 hours, 4 hours, and 8 hours (****, P<0.0001), and TNF-α was significantly decreased at 1 hour and 2 hours (2 hours, ****, P<0.0001). All results were analyzed using an ANOVA statistical program (Figure 7).
[0114] According to the results of the above examples, GKB101 has a strong binding affinity to WARS1 of less than single nM, and has a neutralizing ability to reduce the expression of cytokines expressed by WARS1 in vivo and in vitro. As described above, the composition of the present invention is expected to have high industrial applicability, since it can be used for the purpose of developing an antibody drug that specifically detects and targets WARS1, which is the top substance that induces early hyperinflammation in response to infection, and inhibits it.
[0115] Although each embodiment of the present invention has been described above, a person having ordinary knowledge in the relevant technical field can modify and change the present invention in various ways by adding, changing, deleting or adding elements without departing from the concept of the present invention as described in the claims, and this can also be said to be within the scope of the claims of the present invention.
Claims
1. An antibody or antigen-binding fragment thereof that specifically binds to WARS comprising a heavy chain variable region (VH) having a heavy chain CDR1 of SEQ ID NO: 3 in the sequence listing, a heavy chain CDR2 of SEQ ID NO: 4 in the sequence listing, and a heavy chain CDR3 of SEQ ID NO: 5 in the sequence listing, and a light chain variable region (VL) having a light chain CDR1 of SEQ ID NO: 6 in the sequence listing, a light chain CDR2 of SEQ ID NO: 7 in the sequence listing, and a light chain CDR3 of SEQ ID NO: 8 in the sequence listing.
2. The antibody or antigen-binding fragment thereof described in claim 1, which specifically binds to tryptophanyl-tRNA synthetase (WARS) having a heavy chain variable region (VH) of sequence number 1 in the sequence listing and a light chain variable region (VL) of sequence number 2 in the sequence listing.
3. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that it comprises one or more sequences selected from the group consisting of a CL sequence of SEQ ID NO: 21 in the sequence listing, a CH1 sequence of SEQ ID NO: 22 in the sequence listing, a hinge sequence of SEQ ID NO: 23 in the sequence listing, a CH2 sequence of SEQ ID NO: 24 in the sequence listing, and a CH3 sequence of SEQ ID NO: 25 in the sequence listing.
4. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that the fragment is a fragment selected from the group consisting of Fab, F(ab')2, Fd, sdFv, Fv, scFv and tetramer, or a binding form of the fragment and Fc.
5. A polynucleotide encoding the antibody or antigen-binding fragment thereof of claim 1.
6. A vector comprising the polynucleotide of claim 5.
7. A cell transformed with the vector of claim 6.
8. A method for producing an antibody or antigen-binding fragment thereof that specifically binds to WARS, comprising culturing the cell of claim 7 under conditions in which the polynucleotide is expressed, and recovering the polypeptide.
9. A method for the specific detection of WARS, comprising contacting the antibody or antigen-binding fragment thereof of claim 1 with a sample.
10. A composition for the specific detection of WARS, comprising the antibody or antigen-binding fragment thereof of claim 1.
11. A composition for diagnosing an infectious disease comprising the antibody or antigen-binding fragment thereof of claim 1.
12. The diagnostic composition according to claim 11, wherein the infectious disease is an infectious inflammatory disease.
13. The diagnostic composition according to claim 12, wherein the infectious inflammatory disease is sepsis or septic shock.
14. A pharmaceutical composition for treating an infectious disease comprising the antibody or antigen-binding fragment thereof of claim 1, a polynucleotide encoding said antibody or antigen-binding fragment thereof, a vector containing said polynucleotide, or a cell transformed with said vector.
15. The pharmaceutical composition for treating an infectious disease according to claim 14, wherein the infectious disease is an infectious inflammatory disease.
16. The pharmaceutical composition for treating an infectious disease according to claim 15, wherein the infectious inflammatory disease is sepsis or septic shock.
Citation Information
Patent Citations
Human antibodies against S. aureus hemolysin A toxin
JP2020504759A
Antibody specifically binding to tryptophanyl-tRNA synthetase protein and uses thereof
KR1020210010236A
